Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a).
about
Apolipoprotein B RNA editing enzyme-deficient mice are viable despite alterations in lipoprotein metabolismSusceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B.Proteomic analysis of aortae from human lipoprotein(a) transgenic mice shows an early metabolic response independent of atherosclerosis.Lipoprotein(a): an emerging cardiovascular risk factor.Farnesoid X receptor represses hepatic human APOA gene expression.Lipoprotein(a): an elusive cardiovascular risk factorLipoprotein(a): biology and clinical importanceInhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic miceLow density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a).Inhibition of neointima formation through DNA vaccination for apolipoprotein(a): a new therapeutic strategy for lipoprotein(a)Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urineParadoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice.Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice.Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus.Mouse models of atherosclerosis: explaining critical roles of lipid metabolism and inflammation.Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis.Development of lipoprotein(a) siRNAs for mechanism of action studies in non-human primate models of atherosclerosis.Lipoprotein(a) in health and disease.Atherosclerosis and the mouse: a decade of experience.Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics.Endothelium-dependent vasorelaxation in the aorta of transgenic mice expressing human apolipoprotein(a) or lipoprotein(a).Apolipoprotein B production reduces lipotoxic cardiomyopathy: studies in heart-specific lipoprotein lipase transgenic mouse.Adenovirus-mediated apo(a)-antisense-RNA expression efficiently inhibits apo(a) synthesis in vitro and in vivo.Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a].
P2860
Q24616407-9FC85E64-914A-4B84-8DAC-2255AC333393Q28513997-27AFF387-FA64-4060-877A-B725A6F6A077Q33844451-60AF9429-9BE0-44E5-9D8B-F649B23BC672Q34140556-E791017D-45D0-4E3E-B26D-33168CE3E714Q35081894-C0552CEF-CD1A-4774-B3B3-A3377668F2D2Q35187047-12E60030-1079-4820-84C3-D8A1406052DEQ35746190-5F372D7A-BB21-4B25-A454-76D7E3FAF586Q35754367-9A46180C-780D-4EDD-8A00-0A241B149797Q35782654-751D6A1A-C9A8-4597-AF61-06D221E37EF3Q36476141-8CDC81EB-8339-4B31-836A-B1F23A0AA13FQ36736883-0A42FB5A-FA64-451D-9B56-2D4F8D47B0FFQ37361631-FA311116-37D8-447B-802B-CADE58319D10Q37368611-6BE4B24C-0BB5-4654-9237-715A341338ACQ37370315-B25C00FE-3D89-4839-8A07-D5160F3A5661Q37372596-8B422570-F452-4379-906E-030E5AA23998Q38077675-7A8C622F-30D6-4D0F-93DC-A6A64B9D6893Q38701405-5ACF9347-F18A-4DE2-AC1F-9EBA546D4027Q38918257-EB9AD40A-E3B3-48C1-8EBB-1C4578DCF951Q41300659-E3A7B7AD-1FC1-47ED-AF19-D4EDBBBF8B16Q41548189-AC23AE73-41E8-4E14-8A2B-F038A74AE806Q41728631-818D5EB9-3B75-47EF-8A8D-84C4EFF48C24Q42499863-AA01E1C5-A506-4796-AF73-E92C828C35E8Q44666420-D684665A-C6D6-4C11-A6DE-E797E6EAC39BQ45876542-0B038890-B317-4811-A5C3-5EDCBB0B930DQ46693462-97EECD40-5E11-4640-809F-7C174107F9B0
P2860
Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a).
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a).
@ast
Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a).
@en
type
label
Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a).
@ast
Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a).
@en
prefLabel
Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a).
@ast
Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a).
@en
P2093
P2860
P356
P1476
Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a).
@en
P2093
J Verstuyft
M J Callow
R Tangirala
W Palinski
P2860
P304
P356
10.1172/JCI118203
P407
P577
1995-09-01T00:00:00Z